AXP vs SGMO · P/E 20, rev $21.73B vs rev $57.8M
American Express Company (AXP) versus Sangamo Therapeutics Inc (SGMO) — a side-by-side from cached financials, not a winner call.
American Express Company (AXP) is a credit services company listed on US.
Sangamo Therapeutics Inc (SGMO) is a biotechnology company listed on NASDAQ.
Latest reported AXP revenue for 2026-06-30 was $21.73B. Net income was $6.08B. AXP currently screens at market cap $215.94B and trailing P/E 19.8.
Latest reported SGMO revenue for 2024-12-31 was $57.8M. Net income was -$97.9M. Revenue was down 67.2% from 2023-12-31 to 2024-12-31. SGMO currently screens at market cap $74.6M.
AXP currently screens at market cap $215.94B and trailing P/E 19.8. SGMO currently screens at market cap $74.6M.
Not investment advice. Open the AXP and SGMO stock pages for the full models.
Not investment advice.